TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Sarah A Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.